Antibodies that immunospecifically bind to TRAIL receptors

• US 20060062786A1
• Filed: 09/08/2005
• Published: 03/23/2006
• Est. Priority Date: 11/08/2000
• Status: Abandoned Application

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Rosen, Craig A., Ruben, Steven M., Roschke, Viktor, Salcedo, Theodora W.
• Application Number:
  US11/221,281
• Publication Number:
  US 20060062786A1
• Time in Patent Office: Days
• US Class Current: 424/143.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptors. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TRAIL receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor.

Claims

1. An isolated antibody comprising an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence that is at least 90% identical to a VH domain of any one of SEQ ID NOS;

42, 44, or 46;

(b) an amino acid sequence that is at least 90% identical to a VL domain of any one of SEQ ID NOS;

43, 45, or 47; and

(c) both (a) and (b);

wherein said antibody immunospecifically binds to TR4.

2. The antibody of claim 1 wherein the amino acid sequence is selected from the group consisting of:

(a) the amino acid sequence of a VH domain of any one of SEQ ID NOS;

42, 44, or 46;

(b) the amino acid sequence of a VL domain of any one of SEQ ID NOS;

43, 45, or 47; and

(c) both (a) and (b).

3. The antibody of claim 1 wherein the antibody is selected from the group consisting of:

(a) a whole immunoglobulin molecule;

(b) an scFv;

(c) a monoclonal antibody;

(d) a human antibody;

(e) a chimeric antibody;

(f) a humanized antibody;

(g) a Fab fragment;

(h) an Fab′

fragment;

(i) an F(ab′

)2;

(j) an Fv; and

(k) a disulfide linked Fv.

4. The antibody of claim 1 wherein the antibody is multimeric.

5. The antibody of claim 1 wherein the antibody is crosslinked.

6. The antibody of claim 1 wherein the antibody has a dissociation constant (K_D) selected from the group consisting of:

(a) a dissociation constant (K_D) between 10<sup>−

7</sup> M and 10<sup>−

8</sup> M;

(b) a dissociation constant (K_D) between 10<sup>−

8</sup> M and 10<sup>−

9</sup> M;

(c) a dissociation constant (K_D) between 10<sup>−

9</sup> M and 10<sup>−

10</sup> M;

(d) a dissociation constant (K_D) between 10<sup>−

10</sup> M and 10<sup>−

11</sup> M;

(e) a dissociation constant (K_D) between 10<sup>−

11</sup> M and 10<sup>−

12</sup> M; and

(f) a dissociation constant (K_D) between 10<sup>−

12</sup> M and 10<sup>−

13</sup> M.

7. The antibody of claim 1 wherein the antibody is associated with a detectable label.

8. The antibody of claim 1 wherein the antibody is conjugated to a therapeutic or cytotoxic agent.

9. The antibody of any one of claim 1 which is attached to a solid support.

10. An isolated cell that produces the antibody of claim 1.

11. The antibody of claim 1 wherein the antibody is an agonist of a TR4 receptor.

12. The antibody of claim 1 wherein the antibody is an antagonist of TR4.

13. A method of treating, preventing or ameliorating a cancer comprising administering the antibody of claim 1 or a composition containing the antibody of claim 1 to an animal.

14. The method of claim 13, wherein the antibody is administered in combination with a chemotherapeutic agent.

15. A method of inhibiting the growth of or killing TR4 expressing cells, comprising administering to an animal in which such inhibition of growth or killing of TR4 receptor expressing cells is desired, the antibody of claim 1 or a composition containing the antibody of claim 1 in an amount effective to inhibit the growth of or kill TR4 expressing cells.

16. A method of detecting expression of a TR4 polypeptide comprising:

(a) assaying the expression of a TR4 polypeptide in a biological sample from an individual using the antibody of claim 1;

and

(b) comparing the level of a TR4 polypeptide with a standard level of a TRAIL receptor polypeptide.

17. A method of detecting, diagnosing, prognosing, or monitoring cancers and other hyperproliferative disorders comprising:

(a) assaying the expression of a TR4 polypeptide in a biological sample from an individual using the antibody of claim 1;

and

(b) comparing the level of a TR4 polypeptide with a standard level of TR4 polypeptide.

18. A kit comprising the antibody of claim 1.

19. A hybridoma cell line selected from XF2-1A12, XF2-1G3, XF2-1G5, XF2-2D2, XF2-2H1, XF24C2, XF2-4F7, XF24G8, XF24H5, XF2-4H11, XF2-18A10, XF2-19C10, or XF2-23H7, or the hybridoma cell lines contained in ATCC Deposit Nos. PTA-3149, PTA-2687, PTA-3369, PTA-2730, PTA-2729, PTA-2728, PTA-3368, and PTA-2731.

20. An antibody that binds TR4 selected from the group consisting of:

(a) the antibody expressed by the 7.1.3 cell line contained in ATCC Deposit No. PTA-3149;

(b) the antibody expressed by the 7.3.1 cell line contained in ATCC Deposit No. PTA-2687;

(c) the antibody expressed by the 7.3.2 cell line contained in ATCC Deposit No. PTA-2687;

(d) the antibody expressed by the 7.3.3 cell line contained in ATCC Deposit No. PTA-3369;

(e) the antibody expressed by the 7.8.1 cell line contained in ATCC Deposit No. PTA-2730;

(f) the antibody expressed by the 7.8.2 cell line contained in ATCC Deposit No. PTA-2730;

(g) the antibody expressed by the 7.8.3 cell line contained in ATCC Deposit No. PTA-2730;

(h) the antibody expressed by the 7.10.1 cell line contained in ATCC Deposit No. PTA-2729;

(i) the antibody expressed by the 7.10.2 cell line contained in ATCC Deposit No. PTA-2729;

(j) the antibody expressed by the 7.10.3 cell line contained in ATCC Deposit No. PTA-2729;

(k) the antibody expressed by the 7.12.1 cell line contained in ATCC Deposit No. PTA-2728;

(l) the antibody expressed by the 7.12.3 cell line contained in ATCC Deposit No. PTA-2728;

(m) the antibody expressed by the 8.3.1 cell line contained in ATCC Deposit No. PTA-2731;

(n) the antibody expressed by the 8.3.2 cell line contained in ATCC Deposit No. PTA-2731;

(o) the antibody expressed by primary hybridoma isolate XF2-1A12;

(p) the antibody expressed by primary hybridoma isolate XF2-1G3;

(q) the antibody expressed by primary hybridoma isolate XF2-1G5;

(r) the antibody expressed by primary hybridoma isolate XF2-2D2;

(s) the antibody expressed by primary hybridoma isolate XF2-2H1;

(t) the antibody expressed by primary hybridoma isolate XF2-4C2;

(u) the antibody expressed by primary hybridoma isolate XF2-4F7;

(v) the antibody expressed by primary hybridoma isolate XF24G8;

(w) the antibody expressed by primary hybridoma isolate XF24H5;

(x) the antibody expressed by primary hybridoma isolate XF24H11;

(y) the antibody expressed by primary hybridoma isolate XF2-18A10;

(z) the antibody expressed by primary hybridoma isolate XF2-19C10; and

(aa) the antibody expressed by primary hybridoma isolate XF2-23H7.